Autopsy report · NCT00705822

Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

“low recruitment rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 10 months after it had already started.
• Ran for about 2 years 11 months before it stopped.
• 54 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Prostatic Neoplasms

Interventions

Docetaxel + Estramustine + Hydrocortisone; Docetaxel + Prednisone

Participants

54

Sites

1

Countries

Spain

Trials that died the same way

• NHFOV Versus NCPAP to Prevent Exubation Failure
  “Poor recruitment rate” (95% match in meaning)
• Prospective Randomized Controlled Trial of Obstructed Defecation Surgery
  “Due to low recruitment rate” (90% match in meaning)
• Carbon Ion Radiotherapy for Hepatocellular Carcinoma
  “Slow recruitment rate” (89% match in meaning)
• Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
  “Low recruitment” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.